Introduction {#Sec1}
============

Colonoscopy may be one of the most frequent elective procedures, particularly in adults aged 45 years and older in which it is part of a recommended colorectal cancer screening program \[[@CR1]\]. Complications from colonoscopy and the bowel preparation that precedes the procedure occur at a low frequency \[[@CR2]\]; however, reduction of risks that are attributable to the bowel preparation may be achieved with the use of effective and safer products \[[@CR3]\].

To date, the safest bowel preparations are generally recognized to be the isotonic formulations composed of polyethylene glycol (PEG) and electrolytes, which have been in use since the early 1980s. These preparations induce a voluminous osmotic diarrhea and are designed to prevent electrolyte and water gains or losses \[[@CR4], [@CR5]\]. However, adequate cleansing for colonoscopy with these preparations requires ingestion of a large volume of solution, typically about 4 L. In response to patient demands for lower volume and more tolerable preparations, a small volume hypertonic saline preparation based on sodium phosphate was promoted in the 1990s \[[@CR6]\]. This product similarly induced an osmotic diarrhea, but unlike the isosmotic preparations, supplemental water was required to prevent dehydration. Rare case reports of acute renal failure eventually emerged followed by publication of kidney biopsy data showing renal calcification in association with use of the phosphate preparations \[[@CR7]\]. The United States (US) Food and Drug Administration (FDA) subsequently issued a warning resulting in the voluntary removal from the market of the liquid form of the sodium phosphate bowel preparation and a "black box" warning for the tablet preparations \[[@CR8]\].

A new hypertonic saline preparation has been introduced based on a combination of the sulfate salts of sodium, potassium, and magnesium (SUPREP^®^ \[oral sulfate solution (OSS)\], Braintree Laboratories Inc.) \[[@CR9]\]. Studies of the physiology of both phosphate and sulfate hypertonic preparations in normal volunteers showed that the use of the phosphate preparation, but not the sulfate formulation, markedly increased urine phosphate concentration with a corresponding increase in propensity for formation of calcium precipitates, despite vigorous hydration of study subjects \[[@CR10]\]. Clinical studies of the sulfate formulation have demonstrated its safety and efficacy under the rigorous conditions inherent in formal clinical trials where it appears to be equally safe to the PEG-based preparations \[[@CR9]--[@CR11]\]. However, real-world clinical experience can vary in ways not observed within the confines of clinical trials. For example, based on the phosphate experience, because the product requires ingestion of supplemental water to replace fluid loss induced by the osmotic diarrhea, some patients may not consume sufficient replacement water, which results in problems associated with dehydration. Additionally, rare unanticipated outcomes are more likely to be detected in large, observational studies.

This study compared the incidence of treatment-emergent adverse events (TEAEs) which may occur in association with the recently approved OSS bowel preparation to other common bowel preparations in patients aged 45 years or older who underwent screening colonoscopy. This is the first report that examines the incidence of TEAEs in clinical practice for any bowel preparation to other available prescription bowel preparations in a large population of screening patients.

Methods {#Sec2}
=======

Study Design {#Sec3}
------------

This retrospective, real-world, observational study was undertaken as a post-marketing pharmacovigilance safety study of OSS in screening colonoscopy patients. The study was approved by the New England Institutional Review Board and was agreed by the FDA. Data were obtained from a de-identified health insurance claims data source (MarketScan^®^ Commercial Claims and Encounters Database and Medicare Supplemental and Coordination of Benefits Database, Truven Health Analytics, Inc.). Laboratory results data were also obtained (Truven Health Analytics, Inc.). Health insurance claims included inpatient, outpatient, and prescription drug claims for over 170 million individuals in the USA annually from approximately 90 large employers and health plans, with insurance provided under various fee-for-service and capitated health plans. The data include commercially insured beneficiaries aged 0--64 years and beneficiaries aged 65 and older with Medicare coverage in addition to commercial insurance. The study period included claims from August 1, 2009, through December 31, 2011, with an observation period from August 1, 2010, through December 31, 2011.

The primary objective was to describe and compare, in real-world settings, the incidence of TEAEs observed associated with OSS to other prescription bowel preparations occurring at any time in the 3 months following administration for screening colonoscopy in an adult population in the USA.

Study Population {#Sec4}
----------------

Patients who received a bowel preparation followed by a screening colonoscopy were included in the study. Specifically, patients who met the following criteria were included:had a claim for a screening colonoscopy;had a claim for one of the following bowel preparations within the 60 days prior to the screening colonoscopy: OSS (i.e., SUPREP^®^); PEG-3350 and electrolytes for oral solution (generic or Clenz-Lyte™ \[Paddock Laboratories Inc.\], Colyte^®^ \[Meda Pharmaceuticals Inc.\], GaviLyte-C, GaviLyte-G, GaviLyte-N, GoLytely^®^ \[Braintree Laboratories Inc.\], HalfLytely^®^ \[Braintree Laboratories Inc.\], Moviprep^®^ \[Salix Pharmaceuticals Inc.\], NuLytely^®^ \[Braintree Laboratories Inc.\], Trilyte^®^ \[Wallace Pharmaceuticals\]); sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP (Osmoprep^®^, Salix Pharmaceuticals Inc.), or sodium phosphate monobasic monohydrate, sodium phosphate dibasic anhydrous (Visicol^®^, Salix Pharmaceuticals Inc.);had been continuously enrolled in their insurance plan during the 12 months prior to and 3 months following and including the administration of the bowel preparation; andwere 18 years of age or older on the day of the administration of the bowel preparation.

Patients were excluded from the study if they had a claim that included:a prescription for both OSS and one of the other bowel preparations within the 60 days prior to screening colonoscopy (excluded from primary analysis); orevidence that the colonoscopy was not a screening colonoscopy such as: a colon polypectomy in the 12 months prior to the administration of the bowel preparation; ora diagnosis of a gastrointestinal cancer (including colon, esophagus, rectum, small intestine, and stomach) during the 12 months prior to the administration of the bowel preparation.

Screening colonoscopy procedures were identified by the following Healthcare Common Procedure Coding System (HCPCS) codes or combined Current Procedural Terminology (CPT) and International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) diagnosis codes \[[@CR12]\]:HCPCS: G0105 (colorectal cancer screening; colonoscopy on individual at high risk).HCPCS: G0121 (colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk).CPT: 45378 (colonoscopy, flexible, proximal to splenic flexure; with or without colon decompression), 45380 (colonoscopy, flexible, proximal to splenic flexure; with biopsy), 45384 (colonoscopy, flexible, proximal to splenic flexure; with removal of tumor, polyp, or other lesion by hot biopsy forceps or bipolar cautery), 45385 (colonoscopy, flexible, proximal to splenic flexure; with removal of tumor, polyp, or other lesions by snare technique), or 45392 (colonoscopy, flexible, proximal to splenic flexure; with transendoscopic ultrasound-guided intramural or transmural fine needle aspiration/biopsy) and ICD-9-CM diagnosis code: V76.51 (special screening for malignant neoplasm---colon) or V16.0 (family history of malignant neoplasm---gastrointestinal tract).

The bowel preparations were identified by National Drug Code.

Patients meeting the inclusion and exclusion criteria who had a prescription claim for OSS were included in the OSS cohort. Patients with a prescription claim for one of the other bowel preparations were included in the non-OSS cohort.

Identification of TEAEs {#Sec5}
-----------------------

A TEAE was defined as an event that occurred any time in the 3 months following administration of the bowel preparation for a screening colonoscopy (i.e., follow-up period) and did not occur in the 12 months prior to administration (i.e., baseline period). The 3-month period following administration was chosen as an appropriate follow-up period to observe the TEAEs of interest, particularly renal failure. This period is two months longer than the observation period in a study of safety of bowel preparations in the Medicare population \[[@CR12]\]. A 3-month period was expected to be adequate, as most cases (85.7 %) of acute renal failure occur during the first 2 months after oral phosphate solution \[[@CR7]\]. TEAEs that were examined have been historically associated with bowel preparations and were identified by primary and secondary ICD-9-CM diagnosis codes or out-of-range laboratory values \[[@CR13]\]. TEAEs identified by diagnosis codes included ischemic colitis \[[@CR14]\], aggravation of gout, acute cardiac conditions or events, renal failure and other serious renal diseases, seizure disorders, and serum electrolyte abnormalities. TEAEs identified by laboratory values included troponin leak, elevated creatinine kinase, serum electrolyte abnormalities, and serum uric acid. The codes used to identify the TEAEs are provided in Exhibit 1 of Appendix. Death was identified within the inpatient setting using an indicator for death on the discharge status of the inpatient claim.

Patient risk factors associated with the TEAEs were also identified by ICD-9-CM diagnosis codes during the baseline period. These included arteriosclerosis, brain cancer, diabetes mellitus, gout, heart failure, hyperlipidemia, hypertension, hypotension, liver disease, obesity, peripheral artery disease, previous abdominal surgery (colectomy, colostomy, gastric bypass, stomach stapling), renal disease, stroke, thiazide diuretics use, thyroid disease, and vasculitis \[[@CR15]\].

Analytic Methods {#Sec6}
----------------

Descriptive statistics (i.e., means, standard deviations, medians, ranges) on the demographic and clinical risk factors observed prior to the administration of the bowel preparation were calculated for each bowel preparation cohort (i.e., OSS and non-OSS). To examine the incidence of each TEAE in real-world settings, the unadjusted cumulative incidence of each TEAE and a 95 % confidence interval (CI) were calculated using the Kaplan--Meier method. Differences between the two cohorts were tested using the log-rank Chi-square. To account for any differences between the two cohorts in demographic or clinical risk factors prior to the administration of the bowel preparation, an adjusted cumulative incidence was calculated for each TEAE. Adjusted cumulative incidences and 95 % CIs were calculated using Poisson regression, controlling for demographic and clinical risk factors potentially associated with the bowel preparation and each TEAE, as applicable. The clinical risk factors included in the Poisson regression for each TEAE are provided in Exhibit 1 of Appendix. Demographic and clinical risk factors were removed from the Poisson model if its parameter estimate was not significant (i.e., *p* value greater than 0.10). Follow-up time was used as on offset in the Poisson regression. Differences in the adjusted incidences between the two cohorts were tested using the Wald Chi-square from the Poisson regression. When no events were observed within a cohort, the Clopper--Pearson method was used to calculate an exact 95 % CI. The Fisher's exact test was used to calculate a *p* value when no events were observed in either cohort. Patients with less than 3 months of follow-up due to death, but had no other TEAEs, were censored for the calculation of incidence of each TEAE other than death. The Benjamini--Hochberg false discovery rate procedure \[[@CR16], [@CR17]\] was used to control for multiple comparisons for the unadjusted and adjusted incidences in the main analysis, maintaining a type I error rate of 0.05 which resulted in a claim of significance if the *p* value was less than 0.018 among the unadjusted incidences and less than 0.014 among the adjusted incidences.

The main analysis focused on patients aged 45 years or older because screening colonoscopy is indicated for this age group \[[@CR1]\]. A secondary analysis examined patients aged 18--44 years. Analyses were performed using SAS Software, version 9.1 or higher (SAS Institute, Cary, North Carolina).

Results {#Sec7}
=======

A total of 835,219 patients were identified as having a screening colonoscopy during the study period. Figure [1](#Fig1){ref-type="fig"} presents the effect of the inclusion and exclusion criteria on the study population. Approximately 25 % of patients were excluded because they were not continuously enrolled during the 12 months prior to and 3 months following and including the administration of the bowel preparation so their TEAEs could not be assessed. Another 39 % of patients were excluded because they had no pharmacy claim for a prescription bowel preparation, perhaps due to the physician providing bowel preparation samples and/or recommending over-the-counter products. Thus, just over one-third (35.8 %) of these patients met the inclusion and exclusion criteria for this study, with 287,323 (96.0 %) of these patients aged 45 years or older (OSS: 31,885; non-OSS: 255,438).Fig. 1Study population

Demographic and clinical characteristics of these patients are presented in Table [1](#Tab1){ref-type="table"}. The average age of patients was slightly lower in the OSS cohort compared to the non-OSS cohort (56.6 vs. 57.5 years; *p* \< 0.001) (Table [2](#Tab2){ref-type="table"}). The percent of males was similar between the two cohorts (OSS: 47.1 %, non-OSS: 46.7 %; *p* = 0.178). The most common (≥5 %) TEAE risk factors were arteriosclerosis, diabetes, hyperlipidemia, hypertension, thiazide diuretics use, and thyroid disease. For each TEAE risk factor, except brain cancer, previous abdominal surgery, thyroid disease, and vasculitis, the percent of patients differed significantly (*p* \< 0.05) between cohorts; however, the difference was approximately 2 % or less for all TEAE risk factors.Table 1Demographic and baseline clinical risk factors of an adult screening colonoscopy populationCharacteristicOSS (*N* = 31,885)non-OSS (*N* = 255,438)Age, mean (sd)56.6 (6.4)57.5 (7.3)Male, *n* (%)15,026 (47.1)119,357 (46.7)TEAE risk factors Arteriosclerosis, *n* (%)1657 (5.2)15,704 (6.1) Brain cancer, *n* (%)12 (0.0)114 (0.0) Diabetes, *n* (%)3982 (12.5)35,687 (14.0) Heart failure, *n* (%)237 (0.7)2646 (1.0) Hyperlipidemia, *n* (%)12,397 (38.9)100,904 (39.5) Hypertension, *n* (%)10,836 (34.0)92,760 (36.3) Hypotension, *n* (%)125 (0.4)1357 (0.5) Liver disease, *n* (%)871 (2.7)7503 (2.9) Obesity, *n* (%)838 (2.6)8285 (3.2) Peripheral artery disease, *n* (%)247 (0.8)2414 (0.9) Previous abdominal surgery, *n* (%)970 (3.0)7735 (3.0) Stroke, *n* (%)811 (2.5)7545 (3.0) Thiazide diuretics use, *n* (%)1808 (5.7)17,424 (6.8) Thyroid disease, *n* (%)4013 (12.6)31,862 (12.5) Vasculitis, *n* (%)52 (0.2)378 (0.1)*TEAE* treatment-emergent adverse event Table 2Unadjusted incidence of treatment-emergent adverse events associated with bowel preparations in an adult screening colonoscopy populationTreatment-emergent adverse eventOSS (*N* = 31,885)Non-OSS (*N* = 255,438)*p* value*n*Incidence (%)95 % CI*n*Incidence (%)95 % CI*Identified by diagnosis codes*Overall7362.312.15, 2.4873742.892.82, 2.95\<0.001 Acute cardiac conditions or events4991.561.43, 1.7148451.901.84, 1.95\<0.001 Aggravation of gout750.240.19, 0.297150.280.26, 0.300.151 Death30.010.00, 0.03410.020.01, 0.020.366 Ischemic colitis60.020.01, 0.04560.020.02, 0.030.722 Renal failure and other serious renal diseases670.210.17, 0.278170.320.30, 0.34\<0.001 Seizure disorders850.270.22, 0.338590.340.31, 0.360.040 Serum electrolyte abnormalities1250.390.33, 0.4712530.490.46, 0.520.017*Identified by laboratory valuesN* = 653*N* = 14,432Elevated creatine kinase00.000.00, 0.5650.030.01, 0.081.000Serum electrolyte abnormalities and serum uric acid60.920.41, 2.032191.521.33, 1.730.218Troponin leak00.000.00, 0.5600.000.00, 0.031.000The unadjusted cumulative incidence of each TEAE was calculated using the Kaplan--Meier method. Differences between the two cohorts were tested using the log-rank Chi-square test. When there were no events observed, the Clopper--Pearson method was used to calculate exact CIs. The Fisher's exact test was used to calculate the *p* value for troponin leak*CI* confidence interval

Main Analysis {#Sec8}
-------------

### Unadjusted Incidence {#Sec9}

The unadjusted cumulative incidences of the TEAE categories identified by diagnosis codes are presented in Table [2](#Tab2){ref-type="table"}, and the incidences of the individual TEAEs that made up the categories are presented in Exhibit 2 of Appendix. The overall cumulative incidence was significantly lower in the OSS cohort (2.31 vs. 2.89 %; *p* \< 0.001).

Among the TEAE categories, the incidence of acute cardiac conditions was also significantly lower in the OSS cohort (1.56 vs. 1.90 %; *p* \< 0.001) with the majority of patients with acute cardiac events experiencing arrhythmia (OSS: 230 \[46.1 %\], non-OSS: 2250 \[46.4 %\]; Appendix, Exhibit 2) followed by abnormal electrocardiogram (OSS: 141 \[28.3 %\], non-OSS: 1465 \[30.2 %\]; Appendix, Exhibit 2). Additionally, renal failure/other serious renal diseases (OSS: 0.21 %, non-OSS: 0.32 %; *p* \< 0.001) and serum electrolyte abnormalities (OSS: 0.39 %, non-OSS: 0.49 %; *p* = 0.017) were significantly lower in the OSS cohort.

The cumulative incidences were not significantly different for the following other TEAE categories: seizure disorders (OSS: 0.27 %, non-OSS: 0.34 %; *p* = 0.040), aggravation of gout (OSS: 0.24 %, non-OSS: 0.28 %; *p* = 0.151), death (OSS: 0.01 %, non-OSS: 0.02 %; *p* = 0.366), and ischemic colitis (OSS: 0.02 %, non-OSS: 0.02 %; *p* = 0.722).

Among the patients with laboratory data (OSS: 653 and non-OSS: 14,432), the incidences were also not significantly different for the TEAE categories of serum electrolyte abnormalities/serum uric acid (OSS: 0.92 %, non-OSS: 1.52 %; *p* = 0.218), elevated creatine kinase (OSS: 0.00 %, non-OSS: 0.03 %; *p* = 1.000), and troponin leak (OSS: 0.00 %, non-OSS: 0.00 %; *p* = 1.000).

### Adjusted Incidence {#Sec10}

The adjusted cumulative incidences of the TEAEs identified by diagnosis codes are presented in Table [3](#Tab3){ref-type="table"}, and the incidences of the individual TEAEs that made up the categories are presented in Exhibit 3 of Appendix. The overall cumulative incidence was significantly lower in the OSS cohort (1.61 vs. 1.95 %; *p* \< 0.001). Among the TEAE categories, the incidence of acute cardiac conditions (1.23 vs. 1.47 %; *p* \< 0.001) and renal failure/other serious renal diseases (OSS: 0.10 %, non-OSS: 0.15 %; *p* = 0.004) was also significantly lower in the OSS cohort. The cumulative incidences were not significantly different, for the following other TEAE categories: seizure disorders (OSS: 0.26 %, non-OSS: 0.32 %; *p* = 0.046), serum electrolyte abnormalities (OSS: 0.34 %, non-OSS: 0.41 %; *p* = 0.048), aggravation of gout (OSS: 0.12 %, non-OSS: 0.14 %; *p* = 0.233), death (OSS: 0.01 %, non-OSS: 0.02 %; *p* = 0.369), and ischemic colitis (OSS: 0.02 %, non-OSS: 0.02 %; *p* = 0.743).Table 3Adjusted incidence of treatment-emergent adverse events associated with bowel preparations in an adult screening colonoscopy populationTreatment-emergent adverse eventOSS (*N* = 31,885)Non-OSS (*N* = 255,438)*p* value*n*Incidence (%)95 % CI*n*Incidence (%)95 % CI*Identified by diagnosis codes*Overall7361.611.49, 1.7473741.951.88, 2.02\<0.001 Acute cardiac conditions or events4991.231.12, 1.3548451.471.41, 1.54\<0.001 Aggravation of gout750.120.09, 0.157150.140.12, 0.160.233 Death30.010.00, 0.03410.020.01, 0.020.369 Ischemic colitis60.020.01, 0.04560.020.02, 0.030.743 Renal failure and other serious renal diseases670.100.08, 0.138170.150.13, 0.170.004 Seizure disorders850.260.21, 0.328590.320.30, 0.350.046Serum electrolyte abnormalities1250.340.28, 0.4012530.410.38, 0.430.048*Identified by laboratory valuesN* = 653*N* = 14,432Elevated creatine kinase00.000.00, 0.5650.030.01, 0.081.000Serum electrolyte abnormalities and serum uric acid60.860.38, 1.912191.371.19, 1.580.257Troponin leak00.000.00, 0.5600.000.00, 0.031.000Adjusted incidence was calculated using Poisson regression, controlling for demographic and clinical risk factors. A factor was removed from the Poisson model if its parameter estimate was not significant (i.e., *p* value greater than 0.10). Differences between the two cohorts were tested using the Wald Chi-square. When there were no events observed, the Clopper--Pearson method was used to calculate exact CIs. The Fisher's exact test was used to calculate the *p* value for troponin leak*CI* confidence interval

Among the patients with laboratory data, the incidences were not significantly different for the TEAE categories of serum electrolyte abnormalities/serum uric acid (OSS: 0.86 %, non-OSS: 1.37 %; *p* = 0.257), elevated creatine kinase (OSS: 0.00 %, non-OSS: 0.03 %; *p* = 1.000), and troponin leak (OSS: 0.00 %, non-OSS: 0.00 %; *p* = 1.000).

Secondary Analyses {#Sec11}
------------------

Among patients aged 18--44 years (OSS: 1580, non-OSS: 10,514), the overall cumulative incidences of TEAEs, identified by diagnosis codes, were similar between the two cohorts for both the unadjusted estimate (OSS: 1.33 % \[95 % CI 0.87, 2.03\], non-OSS: 1.46 \[95 % CI 1.25, 1.71\]; *p* = 0.675) and the adjusted estimate (OSS: 1.20 \[95 % CI 0.78, 1.85\], non-OSS: 1.30 \[95 % CI 1.09, 1.55\]; *p* = 0.721). Among patients with laboratory data (OSS: 26 and non-OSS: 582), no TEAEs were observed in the OSS cohort and nine TEAEs were observed in the non-OSS cohort for serum electrolyte abnormalities/serum uric acid.

Relative to patients aged 45 years or older, patients aged 18 to 44 years had lower overall unadjusted cumulative incidence of TEAEs identified by diagnosis codes in the OSS cohort (age 18--44: 1.33 \[95 % CI 0.87, 2.03\]; age 45 + : 2.31 \[95 % CI 2.15, 2.48\]) and in the non-OSS cohort (age 18--44: 1.46 \[95 % CI 1.25, 1.71\], age 45 + : 2.89 \[2.82, 2.95\]).

Discussion {#Sec12}
==========

To our knowledge, this is the largest study of post-colonoscopy TEAEs and the first to compare incidences of these TEAEs between any prescription bowel preparation product and its peers, using real-world data. This study used ICD-9 diagnosis and procedure codes appearing on health insurance claims to define just over half of the TEAEs. ICD-9 codes are recorded for billing purposes and were not developed for research studies. However, it has been shown that ICD-9 codes recorded in administrative claims have extremely high specificity in both ambulatory and inpatient settings \[[@CR18]--[@CR20]\]. The other TEAEs were defined by laboratory tests.

There is a growing need to measure results from real-world clinical practice. Randomized clinical trials typically measure short-term efficacy and safety of a product in a fairly homogenous population and under ideal, controlled conditions compared to placebo. In contrast, real clinical practice requires patient care of a heterogeneous population which is much less controlled and thus more complex. Treatment decisions made in the real clinical practice must consider a wider array of comorbid conditions, competing medications, physician preference, and possible adverse events that may be observed in a larger population or over a longer period of time than included in clinical trials. Outcomes observed in real-world settings reflect this complexity and complement the results observed in clinical trials.

In this study, the non-OSS products were primarily PEG-based preparations (generally considered to be the safest available), which constituted 94.9 % of the non-OSS cohort. Although the incidences for all TEAEs were low for both cohorts, OSS demonstrated statistically significantly lower incidences compared to the non-OSS cohort for overall TEAEs and major events such as acute cardiac and serious renal events.

Unlike other bowel preparations, the safety and pharmacokinetics of OSS have been well studied in patients with renal and hepatic disease \[[@CR21]\]. Unlike sodium phosphate preparations, OSS does not lead to formation of urinary calcium precipitates. Likewise, OSS does not alter the cardiac QTc interval, which is lengthened by oral sodium phosphate \[[@CR22]\].

Similar to the FDA-approved 4-L PEG preparations, OSS had only small effects on the balance of stool fluids and electrolytes \[[@CR10]\]. This has not been demonstrated for other marketed bowel preparations. TEAEs associated with dehydration such as syncope, hypotension, hyperosmolarity, or electrolyte imbalance were also less frequent or equivalent relative to the non-OSS cohort. The differences between OSS and the non-OSS cohorts were not due to differences in age or observed preexisting medical conditions that were accounted for in the adjusted model.

These results are somewhat surprising as the hypertonic preparation might be expected to be less safe than the non-OSS preparations (due to the risk of dehydration if patients do not consume sufficient supplemental water). The results reported here are consistent with the clinical study reports for OSS which showed few adverse events associated with its use \[[@CR9]\]. In this study of 287,323 patients, the overall incidence for TEAEs was low (unadjusted: \<3 %; adjusted: \<2 %), consistent with other reports. Most prior work focused on serious adverse events and/or those with a GI basis \[[@CR23]--[@CR25]\]. For example, in a population-based, matched cohort study of over 50,000 Medicare patients who underwent outpatient colonoscopy, the overall rate of serious gastrointestinal and cardiovascular adverse events was 0.69 and 1.9 %, respectively \[[@CR12]\]. However, the lower incidence of dehydration-related TEAEs associated with OSS suggests that the instructions for hydration that are provided with the product, as well as the general practice of hydration before a colonoscopy, are effective in preventing dehydration.

A possible limitation of this study is the use of a database of predominantly commercially insured beneficiaries. However, if the study data captured the true differences between study cohorts in demographic or clinical risk factors, results from the Poisson regression analysis should be applicable to a non-commercially insured population.

Another limitation is that this study was not designed to detect differences based on different mechanisms. Bowel cleansing preparations are generally categorized as being isotonic (such as PEG-ELS) or hypertonic (such as oral sodium phosphate and OSS).

As expected from prior publications, the incidences of TEAEs were low in both cohorts \[[@CR12], [@CR22]--[@CR25]\]. The observed significant differences may not be readily detected and meaningful at the individual patient level. However, because colonoscopy is performed in a large number of patients each year, many patients are at risk and small differences equate to a meaningful effect on the population and healthcare system. For example, considering that in 2002, approximately 14 million colonoscopies were performed annually \[[@CR26]\], each 0.1 % reduction in TEAE incidence translates into 14,000 fewer events. If all bowel preparation products were associated with similar incidences of TEAEs to that of OSS, nearly 60,000 fewer TEAEs and 50,000 fewer acute cardiac conditions would be expected to occur each year.

Achieving the highest level of safety during elective colonoscopy, in otherwise generally healthy people, is a goal that demands attention. Insurance claims data provide an excellent means for measuring progress toward that goal.

The health insurance claims data only included bowel preparations requiring a prescription. However, nearly half the bowel preparations in use are over-the-counter (OTC) preparations, which are generally not FDA-approved \[[@CR27]--[@CR29]\]. A comparison of TEAEs associated with such preparations to the approved prescription products is clearly needed. Given the low incidence of TEAEs associated with colonoscopy, small changes in the incidence of an event are detectable, as shown here.

In this post-marketing study of TEAEs associated with bowel preparation and screening colonoscopy using a health insurance claims data source of 287,323 patients, the adjusted incidence of TEAEs with OSS was low (\<2 %), with fewer overall events, cardiac events, and renal events than the non-OSS prescription bowel preparations. In conclusion, this study demonstrates that OSS is as safe as or possibly safer than non-OSS prescription products under actual use conditions.

Appendix {#Sec13}
========

See Tables [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"}, and [6](#Tab6){ref-type="table"}.Table 4Exhibit 1. Treatment-emergent adverse event definitions and clinical risk factorsTEAEDefinitionClinical risk factors*Identified by diagnosis codes* ^a^Ischemic colitis^14^Include:\
Vascular insufficiency: 557.0, 557.1, 557.9\
Exclude:\
Preexisting irritable bowel disease: 564.1\
Enterectomy within 14 days of vascular insufficiency: 45.6x, 44120, 44121\
Crohn's disease within 14 days of vascular insufficiency: 555.x\
Ulcerative colitis within 14 days of vascular insufficiency: 556.x\
*Clostridium difficile* enteritis within 14 days of vascular insufficiency: 008.45\
Noninfectious gastroenteritis after colonoscopy: 558.9x\
5-aminosalicylate drug within 14 days of vascular insufficiency: 54569-0313, 66466-4617, 66467-4617, 66467-4617, 57866-4617, 68258-9086, 59762-0104, 59762-5000, 00179-1407, 00179-1485, 25044-0104, 25044-5000, 00904-1152, 51129-1338, 51129-1408, 51129-2976, 51129-2091, 53489-0147, 66267-0747, 66267-0747, 67651-0038, 55289-0176, 59632-0104, 59632-5700, 53002-0297, 54868-1138, 54868-1138, 54868-1139, 17856-0752, 55154-2305, 55887-0834, 66484-0752, 55289-0833, 59628-0752, 00149-0752, 00615-5515, 55154-5951, 55154-2216, 00088-2010, 54092-0189, 54092-0191, 67209-0191, 59632-0105, 00013-0105, 46603-0122, 53014-0726, 68743-0476, 67209-0476\
Colonoscopy/colectomy/surgical pathology of colon biopsy: 88304, 88305, 88307, 88309Heart failure: 428.0--428.4; 428.9\
Hyperlipidemia: 272.0--272.4\
Hypotension: 458.X\
Vasculitis: 273.2; 287.0; 447.6; 447.8; 695.2\
Previous abdominal surgery\
Colectomy: (a) CPT: 44139; 44140; 44141; 44143; 44144; 44145; 44146; 44147; 44150; 44151; 44155; 44156; 44157; 44158; 44160; 44204; 44205; 44206; 44207; 44208; 44210; 44211; 44212; 44213; 44799; 45121; b) ICD-9-CM: 17.31; 17.32; 17.33; 17.34; 17.35; 17.36; 17.39; 45.71; 45.72; 45.73; 45.74; 45.75; 45.76; 45.79; 45.81; 45.82; 45.83\
Colostomy: a) CPT: 44141; 44143; 44144; 44146; 44188; 44206; 44207; 44208; 44320; 44322; 44340; 44345; 44346; 44605; 44799; 45110; 45111; 45123; 45126; 45395; 45563; 45805; 45825; 46710; 46712; 50810; 51597; 57307; 57308; 58240; 88304; 99505; (b) ICD-9-CM: 45.41; 45.43; 45.6; 46.03; 46.1; 46.10; 46.11; 46.13; 46.14; 46.23; 46.32; 46.39; 46.42; 46.43; 46.52; 46.85; 48.5; 48.62; 68.8; 89.33\
Gastric bypass: (a) CPT: 43405; 43610; 43611; 43644; 43645; 43647; 43648; 43651; 43652; 43653; 43659; 43752; 43753; 43754; 43755; 43756; 43757; 43760; 43761; 43770; 43771; 43772; 43773; 43774; 43775; 43800; 43810; 43820; 43825; 43830; 43831; 43832; 43840; 43845; 43846; 43847; 43848; (b) ICD-9-CM: 43.89; 44.31; 44.38; 44.39; 44.91\
Stomach stapling: (a) CPT: 43405; 43610; 43611; 43644; 43846; 43847; b) ICD-9-CM: 44.91Aggravation of goutGout: 274.0X, 274.1X, 274.8X, 274.9Arteriosclerosis: 414.0; 414.3; 440.0--440.4; 440.8; 440.9\
Diabetes mellitus: 249.X; 250.X\
Hyperlipidemia: 272.0--272.4\
Hypertension: 401.0; 401.1; 401.9; 402.X; 404.X; 405.0; 405.1; 405.9\
Thiazide diuretics use: bendroflumethiazide, chlorothiazide, hydrochlorothiazide, indapamide, metolazone, methyclothiazide, polythiazide, quinethazone, trichlormethiazideAcute cardiac conditions or eventsAbnormal electrocardiogram: 794.31\
Acute myocardial infarction: 410.X0, 410.X1, 410.X2\
Angina: 413.0, 413.1, 413.9\
Arrhythmias: 427.0, 427.1, 427.2, 427.3X, 427.4X, 427.6X, 427.8X, 427.9, 785.0\
Cardiac arrest: 427.5\
Congestive heart failure: 428.X, 428.2X, 428.3X, 428.4X\
Hypotension: 458.0, 458.1, 458.21, 458.29, 458.8, 458.9\
Long QT syndrome: 426.82\
Shock: 785.5X\
Syncope/hypotensive syncope: 780.2\
Respiratory arrest: 799.1Diabetes mellitus: 249.X; 250.X\
Hyperlipidemia: 272.0--272.4\
Hypertension: 401.0; 401.1; 401.9; 402.X; 404.X; 405.0; 405.1; 405.9\
Thyroid disease: 240.0; 240.9; 241.0; 241.1; 241.9; 242.0--242.4; 242.8; 242.9; 243; 244.0--244.3; 244.8; 244.9; 245.0--245.4; 245.8; 245.9; 246.0--246.3; 246.8; 246.9\
Obesity: 278.00, 278.01Renal failure and other serious renal diseasesChronic kidney disease: 585.1, 585.2, 585.3, 585.4, 585.5, 585.6, 585.9\
Acute kidney injury/acute renal failure/acute phosphate nephropathy : 584.5--584.9\
Unspecified renal failure: 586Diabetes mellitus: 249.X; 250.X\
Heart failure: 428.0--428.4; 428.9\
Hypertension: 401.0; 401.1; 401.9; 402.X; 404.X; 405.0; 405.1; 405.9\
Liver disease: 570; 571.0--571.6; 571.8; 571.9; 572.0--572.4; 572.8; 573.0--573.4; 573.8; 573.9\
Peripheral artery disease: 443.9Seizure disordersTonic--clonic seizures: 345.10, 345.11, 345.3\
Loss of consciousness: 780.2Stroke: 431, 432.0; 432.1; 432.9; 433.0--433.3; 433.8; 433.9; 434.0; 434.1; 434.9; 435.0--435.3; 435.8; 435.9; 436, 437.0--437.9; 438.0--438.9\
Brain cancer: 191.XSerum electrolyte abnormalitiesElectrolyte imbalance: 276.9\
Hypercalcemia: 275.42\
Hypocalcemia: 275.41\
Hypokalemia: 276.8\
Hypernatremia: 276.0\
Hyponatremia: 276.1\
Hypermagnesemia: 275.2\
Hypomagnesemia: 275.2\
Hyperphosphatemia: 275.3\
Osmolality (high): 276.0\
Osmolality (low): 276.1Brain cancer: 191.X\
Heart failure: 428.0--428.4; 428.9\
Renal disease: 585.1, 585.2, 585.3, 585.4, 585.5, 585.6, 585.9, 584.5--584.9, 586\
Thiazide diuretics use: bendroflumethiazide, chlorothiazide, hydrochlorothiazide, indapamide, metolazone, methyclothiazide, polythiazide, quinethazone, trichlormethiazide*Identified by laboratory values* ^b^Troponin leakTroponin *T*: \>0.09 ng/mLNoneElevated creatine kinaseCreatine kinase: \> 400 U/(males), 150 U/L (females)NoneSerum electrolyte abnormalities and serum uric acidAnion gap = \[Na + K\] − (\[Cl--\] + \[HCO~3~--\]) (high): \>16 mmol/L\
Bicarbonate (low): \<23 mmol/L\
Bilirubin, total (high): \>1 mg/dL\
BUN (high): \>25 mg/dL\
Calcium (low): \<8.5 mg/dL\
Calcium (high): \>10.5 mg/dL\
Chloride (high): \>108 mmol/L\
Creatinine (high): \>1.5 mg/dL\
Magnesium (low): \<1.4 mEq/L\
Magnesium (high): \>2.0 mEq/L\
Osmolality (low): \<280 mOsm/kg\
Osmolality (high): \>296 mOsm/kg\
Phosphorus (high): \>4.5 mg/dL\
Potassium (low): \<3.4 mmol/L\
Sodium (low): \<135 mmol/L\
Sodium (high): \>145 mmol/L\
Uric acid elevations: \>8.5 mg/dL (males), 6.6 mg/dL (females)Electrolyte abnormalities:\
Brain cancer: 191.X\
Heart failure: 428.0--428.4; 428.9\
Renal disease: 585.1, 585.2, 585.3, 585.4, 585.5, 585.6, 585.9, 584.5--584.9, 586\
Thiazide diuretics use: bendroflumethiazide, chlorothiazide, hydrochlorothiazide, indapamide, metolazone, methyclothiazide, polythiazide, quinethazone, trichlormethiazide\
Uric acid:\
Arteriosclerosis: 414.0; 414.3; 440.0--440.4; 440.8; 440.9\
Diabetes mellitus: 249.X; 250.X\
Gout: 274.0X, 274.1X, 274.8X, 274.9\
Hyperlipidemia: 272.0--272.4\
Hypertension: 401.0; 401.1; 401.9; 402.X; 404.X; 405.0; 405.1; 405.9\
Obesity: 278.00, 278.01\
Thiazide diuretics use: bendroflumethiazide, chlorothiazide, hydrochlorothiazide, indapamide, metolazone, methyclothiazide, polythiazide, quinethazone, trichlormethiazide\
Renal disease: 585.1, 585.2, 585.3, 585.4, 585.5, 585.6, 585.9, 584.5--584.9, 586^a^For ischemic colitis, CPT and ICD-9-CM procedure codes for enterectomy and colonoscopy/colectomy/surgical pathology of colon biopsy also were used in addition to ICD-9-CM diagnosis codes. National Drug Code was used to identify 5-aminosalicylate drugs^b^Out-of-range values from Massachusetts General Hospital (MGH) Department of Radiology, MGH Laboratory Handbook: Reference Intervals---MGH Clinical Laboratories. Report generated March 23, 2011. Online Lab Handbook: <http://mghlabtest.partners.org> Table 5Exhibit 2. Unadjusted incidence of treatment-emergent adverse events comprising the overall categoriesTreatment-emergent adverse event (TEAE)SUPREP (*N* = 31,885)Control (*N* = 255,438)*n*Incidence (%)95 % CI*n*Incidence (%)95 % CI*Identified by diagnosis codes*Acute cardiac conditions or events Abnormal electrocardiogram1410.440.38, 0.5214650.570.54, 0.60 Acute myocardial infarction210.070.04, 0.101730.070.06, 0.08 Angina460.140.11, 0.193950.150.14, 0.17 Arrhythmias2300.720.63, 0.8222500.880.85, 0.92 Cardiac arrest10.000.00, 0.02270.010.01, 0.02 Congestive heart failure280.090.06, 0.133390.130.12, 0.15 Hypotension300.090.07, 0.133090.120.11, 0.14 Long QT syndrome00.000.00, 0.0190.000.00, 0.01 Shock50.020.01, 0.04500.020.01, 0.03 Syncope/hypotensive syncope690.220.17, 0.276650.260.24, 0.28 Respiratory arrest00.000.00, 0.0190.000.00, 0.01Renal failure and other serious renal diseases Chronic kidney disease420.130.10, 0.185320.210.19, 0.23 Acute kidney failure260.080.06, 0.123170.120.11, 0.14 Unspecified renal failure120.040.02, 0.07920.040.03, 0.04Seizure disorders Tonic--clonic seizures30.010.00, 0.03410.020.01, 0.02 Loss of consciousness820.260.21, 0.328210.320.30, 0.34Serum electrolyte abnormalities Electrolyte imbalance170.050.03, 0.091080.040.04, 0.05 Hypercalcemia170.050.03, 0.091910.070.06, 0.09 Hypocalcemia100.030.02, 0.06610.020.02, 0.03 Hypokalemia550.170.13, 0.225730.220.21, 0.24 Hypermagnesemia or hypomagnesemia80.030.01, 0.051120.040.04, 0.05 Hyperphosphatemia00.000.00, 0.01340.010.01, 0.02 Hyperosmolality and/or hypernatremia40.010.00, 0.03320.010.01, 0.02 Hyposmolality and/or hyponatremia270.080.06, 0.122750.110.10, 0.12*Identified by laboratory valuesn* = 653*n* = 14,432Serum electrolyte abnormalities and serum uric acid Anion gap (high)00.000.00, 0.5640.030.01, 0.07 Bicarbonate (low)00.000.00, 0.5630.020.01, 0.06 Bilirubin, total (high)00.000.00, 0.56400.280.20, 0.38 BUN (high)30.460.15, 1.42540.370.29, 0.49 Calcium (low)10.150.02, 1.0830.020.01, 0.06 Calcium (high)00.000.00, 0.56160.110.07, 0.18 Chloride (high)00.000.00, 0.56260.180.12, 0.26 Creatinine (high)00.000.00, 0.56130.090.05, 0.16 Magnesium (low)10.150.02, 1.08190.130.08, 0.21 Magnesium (high)00.000.00, 0.5660.040.02, 0.09 Osmolality (low)00.000.00, 0.5620.010.00, 0.06 Osmolality (high)00.000.00, 0.5600.000.00, 0.03 Phosphorus (high)00.000.00, 0.5620.010.00, 0.06 Potassium (low)10.150.02, 1.08220.150.10, 0.23 Sodium (low)00.000.00, 0.56190.130.08, 0.21 Sodium (high)00.000.00, 0.5690.060.03, 0.12 Uric acid elevations00.000.00, 0.5670.050.02, 0.10The unadjusted cumulative incidence of each TEAE was calculated using the Kaplan--Meier method. When there were no events observed, the Clopper--Pearson method was used to calculate exact CIs*CI* confidence interval Table 6Exhibit 3. Adjusted incidence of treatment-emergent adverse events comprising the overall categoriesTreatment-emergent adverse eventOSS (*N* = 31,885)Non-OSS (*N* = 255,438)*n*Incidence (%)95 % CI*n*Incidence (%)95 % CI*Identified by diagnosis codes*Acute cardiac conditions or events Abnormal electrocardiogram1410.360.30, 0.4214650.460.42, 0.49 Acute myocardial infarction210.050.03, 0.081730.050.04, 0.06 Angina460.080.06, 0.123950.090.07, 0.10 Arrhythmias2300.630.55, 0.7222500.760.72, 0.80 Cardiac arrest10.000.00, 0.01270.010.00, 0.01 Congestive heart failure280.050.03, 0.073390.070.05, 0.08 Hypotension300.070.05, 0.103090.090.07, 0.10 Long QT syndrome00.000.00, 0.0190.000.00, 0.01 Shock50.020.01, 0.04500.020.01, 0.03 Syncope/hypotensive syncope690.170.14, 0.226650.210.18, 0.23 Respiratory arrest00.000.00, 0.0190.000.00, 0.01Renal failure and other serious renal diseases Chronic kidney disease420.070.05, 0.095320.100.08, 0.11 Acute kidney failure260.040.02, 0.063170.050.04, 0.06 Unspecified renal failure120.020.01, 0.03920.020.01, 0.02Seizure disorders Tonic--clonic seizures30.010.00, 0.03410.020.01, 0.02 Loss of consciousness820.250.20, 0.318210.310.29, 0.33Serum electrolyte abnormalities Electrolyte imbalance170.050.03, 0.081080.040.03, 0.05 Hypercalcemia170.040.03, 0.071910.060.05, 0.07 Hypocalcemia100.030.01, 0.05610.020.01, 0.02 Hypokalemia550.140.10, 0.185730.170.15, 0.19 Hypermagnesemia or hypomagnesemia80.020.01, 0.051120.040.03, 0.05 Hyperphosphatemia00.000.00, 0.01340.010.00, 0.01 Hyperosmolality and/or hypernatremia40.010.00, 0.03320.010.01, 0.02 Hyposmolality and/or hyponatremia270.080.05, 0.112750.100.08, 0.11*Identified by laboratory valuesn* = 653*n* = 14,432Serum electrolyte abnormalities and serum uric acid Anion gap (high)00.000.00, 0.5640.030.01, 0.07 Bicarbonate (low)00.000.00, 0.5630.010.00, 0.06 Bilirubin, total (high)00.000.00, 0.56400.240.17, 0.35 BUN (high)30.380.12, 1.20540.300.22, 0.41 Calcium (low)10.090.01, 0.7730.010.00, 0.05 Calcium (high)00.000.00, 0.56160.080.04, 0.15 Chloride (high)00.000.00, 0.56260.180.12, 0.26Creatinine (high)00.000.00, 0.56130.060.03, 0.11 Magnesium (low)10.150.02, 1.05190.120.08, 0.19 Magnesium (high)00.000.00, 0.5660.040.02, 0.09 Osmolality (low)00.000.00, 0.5620.010.00, 0.05 Osmolality (high)00.000.00, 0.5600.000.00, 0.03 Phosphorus (high)00.000.00, 0.5620.010.00, 0.06 Potassium (low)10.120.02, 0.88220.110.07, 0.19 Sodium (low)00.000.00, 0.56190.130.08, 0.21 Sodium (high)00.000.00, 0.5690.060.03, 0.12 Uric acid elevations00.000.00, 0.5670.020.01, 0.06Adjusted incidence was calculated using Poisson regression, controlling for patient factors including demographic characteristics and clinical risk factors. Differences between the two cohorts were tested using the Wald Chi-square. A patient factor was removed from the Poisson model if the parameter estimate was not significant (i.e., *p* value greater than 0.10). When there were no events observed, the Clopper--Pearson method was used to calculate exact CIs. The Fisher's exact test was used to calculate the *p* value for troponin leak*CI* confidence interval
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